All News

Article

Biosimilar Slow Growth in USA

Jack Cush, MD

A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and autoimmune disorders. The following are takeaway bullets from this informative article.

Article

Gut microbiome changes linked to onset of RA

EurekAlert!

Changes in the make-up of the gut microbiome are linked to the onset of clinically evident rheumatoid arthritis in those at risk of the disease because of genetic, environmental, or immunological factors, suggests research published online in the 

Dr. John Cush Tweet
RheumNow
VA #RA registry study of 263 RA-ILD pts (mean 69 yrs, 95% male, 73% W, 85% smokers), finds the MUC5B promoter variant in 33.5%. While the MUC5B variant is assoc w/ RA-ILD risk, it does not predict survival or mortality. Other genetic & nongenetic factor must be responsible… https://t.co/sr1AtAZRDT https://t.co/KKD7RLnIqR
Dr. John Cush Tweet
RheumNow
Memory B cells are dysfunctional in #SLE. They are anergic B cell receptor signalling, but responsiveness to Toll-like receptor (TLR) and type I interferon signalling. BCR hyporesponsiveness of memory B cells may explain failure non-depleting B cell Rx in SLE… https://t.co/naBYtgLBGd https://t.co/5sJibS9esn
Dr. John Cush Tweet
RheumNow
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD. 30% of ILD has cough Chest CT 91% sensitive, 71% specific 5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/9pET497zjC https://t.co/P8XVlVmmLd
Dr. John Cush Tweet
RheumNow
Serial MRI study of SI & lumbar (LS) joints in 24 early axSpA (Sxs < 5.5yrs) over 3 yrs, showed: - SIJ developed bone marrow edema, sclerosis & erosion. - LS: fat lesions decreased & erosions increased. - Facet joint inflammation (in t0) significantly influenced yr 3. LS bony… https://t.co/COlFAXVE1x https://t.co/4Xs9ngJN4w
Dr. John Cush Tweet
RheumNow
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush Tweet
RheumNow
Advances in the treatment of autoimmune hepatitis Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure.… https://t.co/6GtWZ8tDDv https://t.co/YuJrcOyaGP
Dr. John Cush Tweet
RheumNow
Literature review of the treatment of IgA Vasculitis (Henoch–Schönlein Purpura) suggests: - Glucocorticoids are 1st -line therapy, esp if severe - For minor HSP: colchicine, dapsone, & methotrexate may be useful - Also studied cyclosporine A, tacrolimus, MMF… https://t.co/ZoZX3kyHvo https://t.co/dS82ekuEkv
Dr. John Cush Tweet
RheumNow
EULAR Review of Lifestyle Improvements for Rheumatic Patients A EULAR taskforce evaluated lifestyle behaviors' effects on rheumatic and musculoskeletal diseases (RMDs), finding moderate evidence for minor benefits from certain dietary components. However, high-level evidence on… https://t.co/maaz8W5IUT https://t.co/QiE6Oo1MzX
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×